Dr. Emmett T. Cunningham Jr. is currently Clinical Professor of Ophthalmology at
California Pacific Medical Center, Adjunct Clinical Professor of Ophthalmology at Stanford
University School of Medicine, and Research Associate, The Francis I. Proctor Foundation,
UCSF School of Medicine.
Dr. Cunningham is an internationally recognized authority in the field of infectious and
inflammatory eye disease, having written over 350 publications. Dr. Cunningham was
Clinical Professor and Director of the Uveitis service at NYU from 2002 to 2005, and was
Director of both the Uveitis Service and the Kimura Ocular Immunology Laboratory at the
University of California at San Francisco (UCSF) from 1995 to 2001. Dr. Cunningham
received an MD and MPH in epidemiology and statistics from Johns Hopkins University,
and a PhD in neuroscience from the University of California at San Diego (UCSD) for work
done at The Salk Institute. He completed a residency in ophthalmology and fellowship
training in Corneal Disease, External Disease and Uveitis at UCSF and The Francis I.
Proctor Foundation, a medical retina and uveitis fellowship at Moorfields Eye Hospital in
London, and a fellowship in public health ophthalmology at the Wilmer Eye Institute in
Baltimore, Maryland.
Dr. Cunningham founded and is the Chairman of the Ophthalmology Innovation Summit
(www.ophthalmologysummit.com), a well-attended symposium held in conjunction with
both the annual meeting of the American Academy of Ophthalmology and the American
Society of Cataract and Refractive Surgeons. The Ophthalmology Innovation Summit
brings together leading companies, clinicians, academics and investors in the ophthalmology
space. Dr. Cunningham is on the Board of The Alta Foundation, Annexon Biosciences,
GrayBug Vision, ViewPoint Therapeutics, Lumos Pharma, Galera Therapeutics, and SFJ
Pharmaceuticals Group. He served previously on the Boards of SARcode Biosciences
(acquired by Shire) and Neomend (acquired by Bard).